CDMOs offering Technology Transfer with Cell Therapy
28 published
28 published CDMOs match Technology Transfer and Cell Therapy.
Locations in this set include United States, Japan, United Kingdom, China, Denmark, and Australia.
Capabilities that show up most often in this set: Process Development, CMC Analytical Development, Cell Therapy Manufacturing, Cell-Line Development, and Quality Control Testing.
Matching companies
Minaris Advanced TherapiesPure-play cell and gene therapy CDMO with over 25 years of GMP manufacturing, process development, and biosafety testing expertise. Serves advanced therapy innovators globally from early stage through commercialization.
National ResilienceEnd-to-end CDMO specializing in complex modalities including cell, gene, and RNA-based therapies with North American manufacturing facilities and development capabilities.
Oxford BiomedicaGlobal viral vector CDMO with 30 years of expertise in lentivirus, AAV, and adenovirus manufacturing. Provides end-to-end development and GMP-compliant manufacturing services from preclinical through commercial launch for cell and gene therapy programs.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
PluriFull-service CDMO specializing in cell therapy manufacturing with GMP facilities, proprietary packed-bed expansion technology, and regulatory approvals from FDA, EMA, PMDA, and other key agencies for clinical-stage production.
Porton AdvancedEnd-to-end ATMP CDMO provider offering cell engineering, lentiviral vectors, mRNA/LNP, plasmid development, and GMP manufacturing from preclinical through commercialization with 24 IND approvals across NMPA, FDA, and MedSafe.
RoslinCTRoslinCT is a cell and gene therapy CDMO offering cGMP iPSC banking, process and analytical development, and clinical and commercial manufacturing for autologous and allogeneic programs.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
Markdown mirror: /explore/technology-transfer/cell-therapy.md